Here's What's Pushing Up Esperion Therapeutics Inc. Today
Shares of Esperion Therapeutics Inc. (NASDAQ: ESPR), a clinical-stage biotech focused on reducing cholesterol, popped up again this morning in response to top-line clinical trial results for its lead candidate. The stock was up 19.8% as of 11:10 a.m. EDT during Tuesday's session.
Esperion's wagons are tightly circled around bempedoic acid, its only drug in clinical trials at the moment. This morning, the company announced results from a 60-patient mid-stage study that met its main goal with flying colors.
Image source: Getty Images.
Source: Fool.com
Esperion Therapeutis.Inc. Stock
€2.47
-1.200%
Currently there is a rather positive sentiment for Esperion Therapeutis.Inc. with 17 Buy predictions and 11 Sell predictions.
With a target price of 7 € there is potential for a 183.4% increase which would mean more than doubling the current price of 2.47 € for Esperion Therapeutis.Inc..
